Clinical Trial Details
— Status: No longer available
Administrative data
| NCT number |
NCT00642057 |
| Other study ID # |
H-721 |
| Secondary ID |
|
| Status |
No longer available |
| Phase |
|
| First received |
|
| Last updated |
|
Study information
| Verified date |
March 2023 |
| Source |
Baylor College of Medicine |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Expanded Access
|
Clinical Trial Summary
Although the results of studies looking at tetrabenazine have shown its effectiveness in the
management of hyperkinetic(too much) movement disorders, it has not been made available in
the U.S. The drug must be obtained from Cambridge Laboratories, the distributor, using an
individual IND (#16,161). The cost of the drug is passed on to the patient. The purpose of
the protocol is to provide an efficacious drug, with few side effects, in an attempt to get
rid of a variety of incapacitating dyskinesias (abnormal movements).
Description:
The purpose of the protocol is to provide compassionate use of an efficacious drug, with few
side effects, in an attempt to get rid of a variety of incapacitating dyskinesias (abnormal
movements).
